LUMO

Lumos Pharma, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website lumos-pharma.com
Employees(FY) 32
ISIN US55028X1090

Performance

-0.92%

+7.46%

+43.52%

+70.08%

+35.85%

YTD

+41.18%

Profile

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Advanced Technical Analysis

Technical Analysis of LUMO 2024-11-20

The Moving Average Score of 70 indicates a bullish sentiment, while the Oscillators Score of 43 suggests a neutral stance, and the Technical Score of 56 reinforces a slightly bullish outlook. Overall, the combined scores reflect a generally positive sentiment in the stock, driven primarily by the strong moving average performance.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of LUMO

Stock Rank

Recent News & Updates

2024-10-30 04:05
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62 Annual ESPE Meeting 2024(Yahoo Finance)
2024-10-22 20:00
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)(Globenewswire)
2024-10-09 03:51
Lumos Pharma Inc (LUMO) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Prudence(Yahoo Finance)
2024-09-25 04:05
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024(Globenewswire)
2024-09-04 21:00
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024(Globenewswire)
2024-08-14 21:00
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-01 04:05
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update(Globenewswire)
2024-07-23 04:05
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024(Globenewswire)
2024-06-03 21:00
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024(Globenewswire)
2024-05-20 04:05
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024(Globenewswire)
2024-05-15 15:02
Lumos Pharma Inc (LUMO) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial ...(Yahoo Finance)
2024-05-14 10:53
LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-14 04:15
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results(Globenewswire)
2024-05-09 02:51
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024(Globenewswire)
2024-04-18 04:05
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings(Globenewswire)
2024-03-19 20:00
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042(Globenewswire)
2024-03-08 01:06
Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-07 08:54
LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023(Investorplace)
2024-03-07 03:01
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update(Globenewswire)
2024-02-25 20:00
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024(Globenewswire)
2024-02-05 03:05
Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference(Globenewswire)
2024-01-04 03:05
Lumos Pharma Promotes Pisit Duke Pitukcheewanont, MD to Chief Medical Officer(Globenewswire)
2023-11-21 03:15
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency(Globenewswire)
2023-11-20 03:05
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November(Globenewswire)
2023-11-07 03:35
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates(Globenewswire)
2023-11-07 03:01
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints(Globenewswire)
2023-09-25 21:00
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting(Yahoo Finance)
2023-09-13 20:00
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting(Yahoo Finance)
2023-09-07 04:34
Lumos Pharma Announces Participation in Investor Conferences in September(Yahoo Finance)
2023-08-21 21:00
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.